Lv1
20 积分 2024-10-24 加入
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
2小时前
求助中
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial
3个月前
已完结
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
4个月前
已完结
Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis
4个月前
已关闭
Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis
4个月前
已关闭
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
5个月前
已完结
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
5个月前
已完结
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
5个月前
已关闭
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
5个月前
已完结
Weight regain after cessation of medication for weight management: systematic review and meta-analysis
5个月前
已完结
皖公网安备34019202002308
